Who is sponsoring NCT00630903?

NCT00630903 is sponsored by Madrilenian Group of Cutaneous Lymphomas.

What drugs are being tested in NCT00630903?

Interventions in NCT00630903: PUVA (8MOP + UVA) + IFN, PUVA (8-MOP + UVA).

What condition does NCT00630903 study?

NCT00630903 studies Cutaneous T-Cell Lymphoma (Mycosis Fungoides).

Is NCT00630903 still recruiting?

NCT00630903 is currently terminated. Last updated 6 March 2008.

Last reviewed 2008-03-06 · How we verify

NCT00630903: MF99

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa.

Terminated Phase 4 Last updated 6 March 2008

What this trial tests

Phase 4 trial testing PUVA (8MOP + UVA) + IFN in Cutaneous T-Cell Lymphoma (Mycosis Fungoides) in 54 participants. Terminated before completion.

Timeline

1 January 2000

Primary endpoint
1 January 2003

Quick facts

Lead sponsor	Madrilenian Group of Cutaneous Lymphomas
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	1 January 2000
Primary completion	1 January 2003
Sites	9 locations across Spain

Drugs / interventions tested

PUVA (8MOP + UVA) + IFN — full drug profile →
PUVA (8-MOP + UVA) — full drug profile →

Conditions studied

Cutaneous T-Cell Lymphoma (Mycosis Fungoides) — all drugs for Cutaneous T-Cell Lymphoma (Mycosis Fungoides) →

Sponsor

Madrilenian Group of Cutaneous Lymphomas — full company profile →

Who can join

Adults 18 to 70, any sex, with Cutaneous T-Cell Lymphoma (Mycosis Fungoides). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Efficacy of PUVA vs PUVA + IFN
Time frame: Weeks 4, 8, 12, 16 and 24

Sponsor's own description

The purpose of this study is to determine if combination of PUVA with interferon alpha is better than PUVA alone to treat mycosis fungoides stage Ia Ib or IIa.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, Schmitt J, et al · · 2020 · cited 17× · PMID 32632956 · DOI 10.1002/14651858.cd008946.pub3

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00630903 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Madrilenian Group of Cutaneous Lymphomas
Last refreshed: 6 March 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00630903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing